Maybe.....Takeda wants SM6 more than Amgen."The fact that he...

Maybe.....


Takeda wants SM6 more than Amgen.


"The fact that he received a proteosome inhibitor (Velcade) as part of the treatment protocol with PAT-SM6 is particularly important as Patrys’ next clinical trial will be using a second generation proteosome inhibitor (Kyprolis (Carfilzomib)) in combination with PAT-SM6"


As far as I can tell, Velcade is owned by Millennium pharmaceuticals, which is wholly owned by Takeda.

Takeda has PAB in its portfolio. Anyone know how many shares recently?

Velcade has recently performed well with elotuzumab, another antibody. Elotuzumab is owned by BMS, a large company. Velcade makes a lot of money. PAB would be a cheap add on to make the drug more competitive, espeacially with orphan drug status and its safety profile compared with the current proteasome inhibitors.


Takeda has previously taken over past investments ( Envoy therapeutics).

Anyone else thinking along these lines?


Maybe explains the good announcement sell it down behaviour of the stock.

There has to be some reason for such a poor share price but a willingness by large investors on the 'inside' to buy at 5 cents.